Beta Blocker, Beta₁ Selective; Ophthalmic Agent, Antiglaucoma

Lowering of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension

C

There are no adequate studies in pregnant women. Should be used during pregnancy only if the benefit outweighs potential risk to the fetus. It is not known if levobetaxolol is excreted in human milk. Exercise caution when administering to breast-feeding women.

Hypersensitivity to levobetaxolol or any component; sinus bradycardia; greater than first degree heart block (without a functional pacemaker); cardiogenic shock; decompensated heart failure

Monitor for bronchospasm, bradycardia, or heart failure since topically-applied beta-blockers can sometimes be absorbed systemically. Use caution in patients with a history of heart failure, heart block (without a functional pacemaker), or pulmonary dysfunction. Use caution in labile diabetic patients. Beta-blockers may mask signs of hypoglycemia and hyperthyroidism. May potentiate muscle weakness in myasthenia.

>10%: Ocular: Transient discomfort (11%)

2% to 10%: Ocular: Transient blurred vision (2%)

<2%:

Central nervous system: Anxiety, dizziness, vertigo, headache

Cardiovascular: Bradycardia, heart block, hypertension, hypotension, tachycardia

Dermatologic: Alopecia, dermatitis, psoriasis

Endocrine & metabolic: Diabetes, hyperthyroidism, gout, hypercholesterolemia, hyperlipidemia

Gastrointestinal: Constipation, dyspepsia, taste perversion

Genitourinary: Cystitis

Neuromuscular & skeletal: Hypertonia, arthritis, tendonitis

Ocular: Cataracts, vitreous disorders

Otic: Ear pain, otitis media, tinnitus

Respiratory: Bronchitis, dyspnea, pharyngitis, pneumonia, rhinitis, sinusitis

Miscellaneous: Breast abscess, infection

Information is not available on overdose in humans. Expected events in an overdose might include bradycardia, hypotension, and acute cardiac failure. Treatment should be symptomatic and supportive.

Increased toxicity (hypotension): systemic beta-blockers, catecholamine-depleting agents (reserpine), adrenergic psychotropic agents

Store upright 4°C to 25°C (39°F to 77°F); protect from light

Levobetaxolol is a cardioselective, beta₁-adrenergic receptor antagonist. It is the more active enantiomer of betaxolol. Reduces intraocular pressure by reducing the production of aqueous humor.

Onset: 30 minutes

Maximal effects: 2 hours

Duration: 12 hours

Half-life: 20 hours

Adults: Ophthalmic: Instill 1 drop in affected eye(s) twice daily

Intraocular pressure

No information available to require special precautions

No effects or complications reported

May sting on instillation; do not touch dropper tip to eye; visual acuity may be decreased after administration; apply gentle pressure to the inside corner of the eye during and immediately following instillation to avoid systemic absorption. Stop the medicine if breathing problems occur and contact healthcare provider. Do not use with contact lenses in the eyes. Shake well before using.

Monitor for signs of congestive heart failure, bradycardia, hypotension, respiratory difficulty (bronchospasm). Teach proper instillation of eye drops. Shake well before using. Monitor blood pressure and heart rate. Use caution in diabetics receiving hypoglycemic agents.

Solution, ophthalmic: 0.5% (5 mL, 10 mL, 15 mL)